M. Médus

Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study

D. Mouly, Y. Le Strat, M. Ledrans, 2021, BMJ Open.

Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19

C. S. Low, Katarina H. Nelson, James L. Streeter, 2022, Journal of the American College of Cardiology.

Coinfection VIH-VHC : Quelle prise en charge ?

E. Chauvet, M. Médus, H. Aumaître, 2004 .

High seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in Perpignan, France

D. Mouly, Y. Le Strat, M. Ledrans, 2021, medRxiv.

A highly virulent variant of HIV-1 circulating in the Netherlands

Michael J. Rausch, H. Jessen, A. Trkola, 2022, Science.

[Uneven efficacy of Viperfav® antivenom for the treatment of neurotoxic viper envenomations].

L. de Haro, M. Glaizal, L. Tichadou, 2011, Presse medicale.

Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?

A. Fischer, R. Tubiana, L. Cravello, 2020, The Journal of antimicrobial chemotherapy.

[Comparative susceptibility evolution in Escherichia coli from urinary tract infections in outpatients and inpatients at Perpignan hospital in 2002 and 2004].

E. Lecaillon, P. Gueudet, M. Lemort, 2006, Pathologie-biologie.

Prevalence of and factors associated with depression among people living with HIV in France

F. Marion, M. Duracinsky, F. Lert, 2017, HIV medicine.